Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di...
Transcript of Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di...
![Page 1: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/1.jpg)
Talassemie intermedie:
trattamento
Antonio Piga
Università di Torino Dipartimento di Scienze Cliniche e Biologiche
Scuola di Medicina ed Azienda Ospedaliero-Universitaria S. Luigi Gonzaga - Orbassano
S.C.D.U. Pediatria Centro Microcitemie - Centro SQUID
email: [email protected] tel. 011 9026851
![Page 2: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/2.jpg)
thalassemia AND intermedia AND treatment
![Page 3: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/3.jpg)
thalassemia AND intermedia AND treatment
![Page 4: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/4.jpg)
Elisa F., Thalassemia intermedia ? At 2 years of age: Hb 8.2 g dL
To treat or not to treat ?
Thalassemia Centre University of Torino
![Page 5: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/5.jpg)
Thal Major more likely
Thal Intermediamore likely
ClinicalPresentation (yrs) <2 >2
Hb levels (g/dl) <7 8-10
Liver/spleen enlargement Severe Moderate to severe
HematologicalHbF (%) >50 10-50 (up to 100%)
HbA2 (%) <4 >4
GeneticParents High HbA2 in both High HbF or HbA2<4 in one or both
MolecularType of mutation Severe Mild/Silent
Coinheritance of α-thal No Yes
High HbF production No Yes
Hyperunstable Hb variant No Yes
βThal heterozygous + αααor αααα globin genes
No Yes
![Page 6: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/6.jpg)
KEY POINTS FOR LONG-TERM MANAGEMENT OF THALASSEMIA INTERMEDIA
Thalassemia Centre University of Torino
1. TI phenotype may be poorly predictable 2. TI phenotype has a trend to worsen 3. Long term complications may be severe and
irreversible
![Page 7: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/7.jpg)
Age and clinical complications in Thalassemia Intermedia (584 patients on OPTIMAL CARE study)
Taher AT, Blood, 2010
0
5
10
15
20
25
30
35
40
0-1818-35>35 years
Freq
uenc
y of
Com
plic
atio
ns (%
)
![Page 8: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/8.jpg)
……………………………………………………………………………………………………………………….. Medical Attention
Thalassemia Intermedia Clinical Synopsis
Chronic Anemia
10 years 20 years 40 years 30 years 50 years
Thalassemia Centre University of Torino
Diagnosis
![Page 9: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/9.jpg)
KEY POINTS FOR LONG-TERM MANAGEMENT OF THALASSEMIA INTERMEDIA
Thalassemia Centre University of Torino
1. TI phenotype may be poorly predictable 2. TI phenotype has a trend to worsen 3. Long term complications may be severe and
irreversible 4. Prevention of complications requires:
• regular follow-up focused on preclinical markers
![Page 10: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/10.jpg)
Tanno T, Nature Medicine, September 2007
N = 37 13 12 20 40 17 20 22 55
Musallam KM, et al. Blood Cells Mol Dis. 2011;47:232-4.
![Page 11: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/11.jpg)
GDF15 levels correlate with clinical severity score in β-thalassaemia intermedia
r = 0.830 p < 0.001
Mild Moderate Severe
Musallam KM, et al. Blood Cells Mol Dis. 2011;47:232-4.
GD
F15
(pg/
mL)
Clinical severity score
![Page 12: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/12.jpg)
Treatment
Extramedullary erythropoiesis in Thalassemia Intermedia
Symptomatic case
Ileri T, J Pediatr Hemat Oncol, 2009
Full recovery at 12 months
![Page 13: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/13.jpg)
Radiation therapy
Hydroxyurea at 15 mg/kg/d
Hypertransfusion
Neurosurgery
Extramedullary erythropoiesis in Thalassemia Intermedia
Thalassemia Centre University of Torino
Management
![Page 14: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/14.jpg)
Extramedullary erythropoiesis in Thalassemia Intermedia
Tabesh H, J Medical Case Reports, 2011
![Page 15: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/15.jpg)
Thalassemia Intermedia and ischemic lesions
Taher AT, et al. J Thromb Haemost. 2010;8:54-9.c
![Page 16: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/16.jpg)
![Page 17: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/17.jpg)
![Page 18: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/18.jpg)
Hahalis G, Cardiology, 2011
Endothelial dysfunction and subclinical atherosclerosis in asymptomatic thalassemia
intermedia
![Page 19: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/19.jpg)
Ashjazadeh N, Anemia, 2012
Transcranial Doppler sonography (TCD) shows high arterial blood flow velocity in β-thalassemia intermedia
![Page 20: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/20.jpg)
Transcranial
Doppler
Scanning
Thalassemia Centre University of Torino
![Page 21: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/21.jpg)
Thalassemia Centre University of Torino
β Thalassemia Intermedia
![Page 22: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/22.jpg)
Thalassemia Centre University of Torino
β Thalassemia Intermedia
![Page 23: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/23.jpg)
Thalassemia Centre University of Torino
β Thalassemia Intermedia
![Page 24: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/24.jpg)
Thalassemia Centre University of Torino
β Thalassemia Intermedia
![Page 25: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/25.jpg)
Thalassemia Centre University of Torino
Thalassemia Intermedia
![Page 26: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/26.jpg)
Thalassemia Centre University of Torino
β Thalassemia Intermedia
![Page 27: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/27.jpg)
Thalassemia Centre University of Torino
β Thalassemia Intermedia
![Page 28: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/28.jpg)
Thalassemia Centre University of Torino
β Thalassemia Intermedia
![Page 29: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/29.jpg)
KEY POINTS FOR LONG-TERM MANAGEMENT OF THALASSEMIA INTERMEDIA
Thalassemia Centre University of Torino
1. TI phenotype may be poorly predictable 2. TI phenotype has a trend to worsen 3. Long term complications may be severe and
irreversible 4. Prevention of complications requires:
• regular follow-up focused on preclinical markers • early treatment with blood transfusion
![Page 30: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/30.jpg)
Indications for transfusion therapy in thalassaemia intermedia
➥Hb level < 50 g/l ➥Declining Hb level in parallel with profound enlargement of the spleen ➥Severe bony changes ➥Growth failure or poor performance at school ➥Diminished exercise tolerance ➥ Infection ➥Failure of secondary sexual development in parallel with bone age ➥Pregnancy ➥Other specific complications
➥ (e.g. Heart failure, pulmonary hypertension, thromboembolic disease, leg ulcers, priapism)
Taher AT, Brit J Haematol, 2011
![Page 31: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/31.jpg)
o Thal. minor
o Thal. intermedia “mild”
o Thal. intermedia “severe”
o Thal. major
DEGREE OF ANEMIA
ASYMPTOMATIC
MILD
MODERATE
SEVERE
TRANSFUSION-DEPENDENT
NO TRANSFUSION
TRANSFUSION
Thalassemia Centre University of Torino
THALASSEMIA PHENOTYPES AND TRANSFUSION
![Page 32: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/32.jpg)
o Thal. minor
o Thal. intermedia “mild”
o Thal. intermedia “severe”
o Thal. major
THALASSEMIA PHENOTYPES AND TRANSFUSION
DEGREE OF ANEMIA
ASYMPTOMATIC
MILD
MODERATE
SEVERE
TRANSFUSION-DEPENDENT
NO TRANSFUSION
TRANSFUSION
Thalassemia Centre University of Torino
![Page 33: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/33.jpg)
COMPLICATION
Thalassemic stigmata
Hypersplenism
Autoimmune Hemolitic Anemia
Extramedullary erythropoiesis
Leg ulcers
Thromboembolism
Pulmonary Hypertension
Heart Disease
Endocrinopathies
Osteoporosis
Iron overload
Cholelithiasis
Hyperuricuria and Gout
Pseudoxantoma Elasticum
Infections
Role of Blood Transfusion in Preventing or Treating Thalassemia Intermedia Complications
Thalassemia Centre University of Torino
![Page 34: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/34.jpg)
COMPLICATION ROLE IN PREVENTION ROLE IN TREATMENT
Thalassemic stigmata +++ ++ (during chilhood)
Hypersplenism ++ +-
Autoimmune Hemolitic Anemia +++ (if early) -
Extramedullary erythropoiesis +++ ++ (response requires time)
Leg ulcers +++ ++ (response requires time)
Thromboembolism ++ +-
Pulmonary Hypertension ++ ?
Heart Disease ++ (high output HD) +
Endocrinopathies + +-
Osteoporosis + (?) ?
Iron overload + (↑ hepcidin) / - + (↑ hepcidin) / -
Cholelithiasis + -
Hyperuricuria and Gout +++ ++
Pseudoxantoma Elasticum +++ -
Infections ++ ++
Role of Blood Transfusion in Preventing or Treating Thalassemia Intermedia Complications
Thalassemia Centre University of Torino
![Page 35: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/35.jpg)
Thalassemia Centre University of Torino
![Page 36: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/36.jpg)
Thalassemia Centre University of Torino
![Page 37: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/37.jpg)
deferoxamine (DFO)
deferiprone (DFP)
deferasirox (DFX)
Monotherapy Combination of DFO + DFP Potential use of any combination of any 2 or 3 chelators
Iron chelators
![Page 38: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/38.jpg)
Treatment options for Thalassemia Intermedia
Wait & see
Supportive treatment
Sporadic/occasional Transfusion
Regular Transfusion
Iron chelation therapy
Thalassemia Centre University of Torino
![Page 39: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/39.jpg)
KEY POINTS FOR LONG-TERM MANAGEMENT OF THALASSEMIA INTERMEDIA
Thalassemia Centre University of Torino
1. TI phenotype may be poorly predictable 2. TI phenotype has a trend to worsen 3. Long term complications may be severe and
irreversible 4. Prevention of complications requires:
• regular follow-up focused on preclinical markers • early treatment with blood transfusion
5. Alternatives to blood transfusion are problematic
![Page 40: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/40.jpg)
Treatment options for Thalassemia Intermedia
Wait & see
Supportive treatment
Sporadic/occasional Transfusion
Regular Transfusion
Iron chelation therapy
Hydroxyurea
Thalassemia Centre University of Torino
• Antineoplastic chemotherapeutic agent • Ribonucleotide reductase inhibitor • Mechanisms of action in thalassemia
• Increases Hgb F concentration • Decreases bone marrow hyperplasia • Others
![Page 41: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/41.jpg)
Model of regulation of fetal haemoglobin in adults
Adapted from Stamatoyannopoulos, G. Expt Hematology 33 (2005) 259-271
Killing of cycling cells
F cells
F cells
F cells
Heterocellular HPFH
![Page 42: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/42.jpg)
Hemoglobin changes in Thalassemia Intermedia during Hydroxyurea (HU) treatment
Karimi M, Eur J Hematol, 2010
⬅ HU + carnitine + Mg ⬅ HU + carnitine
⬅ HU + Mg
⬅ HU
![Page 43: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/43.jpg)
Echocardiographic parameters in Thalassemia Intermedia during Hydroxyurea (HU) treatment
Karimi M, Eur J Hematol, 2010
HU + carnitine HU + Mg HU + carnitine + Mg
![Page 44: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/44.jpg)
Treatment options for Thalassemia Intermedia
Wait & see
Supportive treatment
Sporadic/occasional Transfusion
Regular Transfusion
Iron chelation therapy
Hydroxyurea (other cytostatic drugs)
Thalassemia Centre University of Torino
![Page 45: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/45.jpg)
Hb F Synthesis Induction
• Cytotoxic drugs • 5-azacytadine, decitabine
• Hydroxyurea • Gamma globin gene promoters
• butyrates: arginine butyrate, sodium phenylbutyrate, isobutyramide, 2-methyl-hydroxy-cinnamic acid (ST7)
• Erythropoietin • Combination of drugs
Thalassemia Centre University of Torino
![Page 46: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/46.jpg)
Treatment options for Thalassemia Intermedia
Wait & see
Supportive treatment
Sporadic/occasional Transfusion
Regular Transfusion
Iron chelation therapy
Hydroxyurea (other cytostatic drugs)
Splenectomy
Thalassemia Centre University of Torino
![Page 47: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/47.jpg)
![Page 48: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/48.jpg)
The OPTIMAL CARE study splenectomized patients: 325/584
Complication Parameter RR 95% CI p value
EMH Splenectomy 0.44 0.26–0.73 0.001 Transfusion 0.06 0.03–0.09 < 0.001 Hydroxyurea 0.52 0.30–0.91 0.022
Pulmonary hypertension Age > 35 years 2.59 1.08–6.19 0.032 Splenectomy 4.11 1.99–8.47 < 0.001 Transfusion 0.33 0.18–0.58 < 0.001 Hydroxyurea 0.42 0.20–0.90 0.025 Iron chelation 0.53 0.29–0.95 0.032
Heart failure Transfusion 0.06 0.02–0.17 < 0.001 Thrombosis Age > 35 years 2.60 1.39–4.87 0.003
Hb ≥ 9 g/dL 0.41 0.23–0.71 0.001 Serum ferritin ≥ 1,000 µg/L 1.86 1.09–3.16 0.023 Splenectomy 6.59 3.09–14.05 < 0.001 Transfusion 0.28 0.16–0.48 < 0.001
Cholelithiasis Age > 35 years 2.76 1.56–4.87 < 0.001 Female 1.96 1.18–3.25 0.010 Splenectomy 5.19 2.72–9.90 < 0.001 Transfusion 0.36 0.21–0.62 < 0.001 Iron chelation 0.30 0.18–0.51 < 0.001
Abnormal liver function Serum ferritin ≥ 1,000 µg/L 1.74 1.00–3.02 0.049
Taher AT, et al. Blood. 2010;115:1886-92.
![Page 49: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/49.jpg)
Complication Parameter RR 95% CI p value
Leg ulcers Age > 35 years 2.09 1.05–4.16 0.036 Splenectomy 3.98 1.68–9.39 0.002 Transfusion 0.39 0.20–0.76 0.006 Hydroxyurea 0.10 0.02–0.43 0.002
Hypothyroidism Splenectomy 6.04 2.03–17.92 0.001 Hydroxyurea 0.05 0.01–0.45 0.003
Osteoporosis Age > 35 years 3.51 2.06–5.99 < 0.001 Female 1.97 1.19–3.27 0.009 Splenectomy 4.73 2.72–8.24 < 0.001 Transfusion 3.10 1.64–5.85 < 0.001 Hydroxyurea 0.02 0.01–0.09 < 0.001 Iron chelation 0.40 0.24–0.68 0.001
Hypogonadism Female 2.98 1.79–4.96 < 0.001 Serum ferritin ≥ 1,000 µg/L 2.63 1.59–4.36 < 0.001 Transfusion 16.13 4.85–52.63 < 0.001 Hydroxyurea 4.32 2.49–7.49 < 0.001 Iron chelation 2.51 1.48–4.26 0.001
Splenectomy is independently associated with an increased risk of most disease-related complications
Taher AT, et al. Blood. 2010;115:1886-92.
The OPTIMAL CARE study splenectomized patients: 325/584 (cont.)
![Page 50: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/50.jpg)
Proportion of splenectomy-free patients in 4 birth cohorts in 295 patients with thalassemia major from 5 Italian Centres
Piga A, Am J Hematol, 2011
![Page 51: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/51.jpg)
Treatment options for Thalassemia Intermedia
Wait & see
Supportive treatment
Sporadic/occasional Transfusion
Regular Transfusion
Iron chelation therapy
Hydroxyurea (other cytostatic drugs)
Splenectomy
Stem Cell Transplantation Ethical concerns on risks/benefits ratio Individual cases only or where optimal care is missing
Thalassemia Centre University of Torino
![Page 52: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/52.jpg)
Treatment options for Thalassemia Intermedia
Wait & see
Supportive treatment
Sporadic/occasional Transfusion
Regular Transfusion
Iron chelation therapy
Hydroxyurea (other cytostatic drugs)
Splenectomy
Stem Cell Transplantation
Thalassemia Centre University of Torino
![Page 53: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/53.jpg)
Treatment options for Thalassemia Intermedia
Wait & see
Supportive treatment
Sporadic/occasional Transfusion
Regular Transfusion
Iron chelation therapy
Hydroxyurea (other cytostatic drugs)
Splenectomy
Stem Cell Transplantation
Modulation of erythropoiesis Thalassemia Centre University of Torino
![Page 54: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/54.jpg)
Khandros E, Hematol Oncol Clin N Am, 2010
Overloading of degradation systems leads to accumulation of a-globin in b-thalassemia
![Page 55: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/55.jpg)
Khandros E, Hematol Oncol Clin N Am, 2010
Examples of protein aggregation diseases
![Page 56: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/56.jpg)
![Page 57: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/57.jpg)
![Page 58: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/58.jpg)
![Page 59: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/59.jpg)
![Page 60: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/60.jpg)
![Page 61: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/61.jpg)
Ginzburg Y, Blood, 2011
Normal and Ineffective Erythropoiesis
![Page 62: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/62.jpg)
![Page 63: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/63.jpg)
![Page 64: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/64.jpg)
Treatment options for Thalassemia Intermedia
Wait & see
Supportive treatment
Sporadic/occasional Transfusion
Regular Transfusion
Iron chelation therapy
Hydroxyurea (other cytostatic drugs)
Splenectomy
Stem Cell Transplantation
Modulation of erythropoiesis Thalassemia Centre University of Torino
![Page 65: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/65.jpg)
Gestione del paziente con Talassemia Intermedia
Thalassemia Centre University of Torino
Pediatra ospedaliero
Pediatra di base
![Page 66: Talassemie intermedie: trattamento...Talassemie intermedie: trattamento Antonio Piga Università di Torino Dipartimento di Scienze Cliniche e Biologiche Scuola di Medicina ed Azienda](https://reader033.fdocuments.us/reader033/viewer/2022041818/5e5bfe1398437d5658032733/html5/thumbnails/66.jpg)